retatrutide nonalcoholic steatohepatitis trial Fatty liver disease was alleviated by Lilly's 'triple-G' obesity drug Current therapies and new developments

In the audience that day was an endocrinologist named John Eng who had a deep background in peptide chemistry (which meant he was well-versed in analyzing genetic and amino-acid sequences)

The regulatory environment for compounded GLP-1 products has tightened significantly in 2026, and consumers should evaluate any telehealth platform's compliance posture within this evolving landscape

Given the biological latency of carcinogenesis, longer-term studies are required to determine whether these signals persist or translate into clinically meaningful reductions in cancer risk

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

This is relevant for long-term titration planning